# Disulfiram for Treatment of Retinal Degeneration

> **NCT05626920** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 30 (estimated)

## Conditions studied

- Inherited Retinal Dystrophy Primarily Involving Sensory Retina

## Interventions

- **DRUG:** Disulfiram 250 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05626920
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-03
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05626920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05626920, "Disulfiram for Treatment of Retinal Degeneration". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05626920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*